Compare Davita Inc (DVA) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Sezzle Inc — how do they compare? Davita Inc trades at $231.61 (market cap $14.92B), while Sezzle Inc trades at $189.4 (market cap $6.15B). The key difference: Davita Inc is far larger — about 2.4× Sezzle Inc's market cap. Which is the better fit depends on your goals.
| DVA | SEZL | |
|---|---|---|
Market Cap | $14.92B | $6.15B |
Sector | Health | Technology |
52-Week High | $235.71 | $188.55 |
52-Week Low | $103.87 | $50.97 |
Enterprise Value | $27.47B | $6.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
SEZL trades at $160.25, down 10.66% over the last session, but maintains a bullish technical outlook with support at $156 and resistance at $165. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.43, and raised full-year guidance. Revenue growth accelerated to 29% year-over-year, with net income margin expanding to 30.83%.
Outlook remains positive given consistent earnings beats and product expansion, though high valuation multiples (P/E 43.68) and a recent securities law investigation pose risks. Analyst consensus is split evenly between Buy and Hold, with a $162 price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
